What Is TB-500?
TB-500 is the synthetic version of Thymosin Beta-4 (Tβ4) — a naturally occurring protein found in virtually every human cell. Unlike BPC-157, which is entirely synthetic, Thymosin Beta-4 is a real endogenous peptide your body already produces. It was first isolated in the 1960s from thymus tissue and has been studied across a wide range of biological contexts including wound healing, cardiac repair, neurological protection, and inflammation. TB-500 refers specifically to the synthetic peptide used in research, which mimics the active region of the full Thymosin Beta-4 molecule.
How It Works: Actin Binding and Cell Migration
TB-500's primary mechanism centers on its ability to bind to actin — one of the most abundant proteins in human cells and the building block of the cytoskeleton. By sequestering actin monomers, TB-500 promotes cell migration, tissue remodeling, and angiogenesis (new blood vessel formation). This is a systemic mechanism, meaning TB-500's effects aren't localized to the injection site the way BPC-157's appear to be. It essentially signals throughout the body to promote repair and reduce inflammation wherever it's needed.
The Human Trial Data — Where It Exists
TB-500 has more human clinical trial data than most research peptides — but it comes from a specific context: cardiac repair. RegeneRx Biopharmaceuticals conducted Phase 1 and Phase 2 trials using Thymosin Beta-4 in patients following acute myocardial infarction (heart attack). The Phase 2 trial showed statistically significant improvements in cardiac function markers in treated patients. These trials establish human safety data and provide mechanistic confirmation — but they don't directly address the musculoskeletal and recovery applications that drive most research interest in TB-500.
Enjoying this? Get weekly peptide research in your inbox →
TB-500 vs BPC-157: Complementary, Not Competing
The two peptides are frequently compared because both are researched for healing, but their mechanisms suggest different roles. BPC-157 drives local angiogenesis and appears to work at or near the site of injury. TB-500's systemic actin-binding mechanism promotes body-wide cell migration to injury sites and manages inflammation more broadly. The theoretical logic behind stacking them is that they address different phases and locations of the repair process — though no clinical data exists on the combination specifically.
Legal Status and Regulatory Context
TB-500 is sold as a research chemical in the US. It is not FDA-approved for any therapeutic use. Like BPC-157, it was added to the FDA's Category 2 list of compounds considered difficult to compound — effectively blocking its availability through US compounding pharmacies. WADA has prohibited it for competitive athletes. Purchasing it for legitimate research purposes exists in the same gray-market framework as other research peptides: technically legal to acquire, but not legal to sell for human consumption.